Literature DB >> 20567770

A collaborative database and computational models for tuberculosis drug discovery.

Sean Ekins1, Justin Bradford, Krishna Dole, Anna Spektor, Kellan Gregory, David Blondeau, Moses Hohman, Barry A Bunin.   

Abstract

The search for molecules with activity against Mycobacterium tuberculosis (Mtb) is employing many approaches in parallel including high throughput screening and computational methods. We have developed a database (CDD TB) to capture public and private Mtb data while enabling data mining and collaborations with other researchers. We have used the public data along with several cheminformatics approaches to produce models that describe active and inactive compounds. We have compared these datasets to those for known FDA approved drugs and between Mtb active and inactive compounds. The distribution of polar surface area and pK(a) of active compounds was found to be a statistically significant determinant of activity against Mtb. Hydrophobicity was not always statistically significant. Bayesian classification models for 220, 463 molecules were generated and tested with external molecules, and enabled the discrimination of active or inactive substructures from other datasets in the CDD TB. Computational pharmacophores based on known Mtb drugs were able to map to and retrieve a small subset of some of the Mtb datasets, including a high percentage of Mtb actives. The combination of the database, dataset analysis, Bayesian and pharmacophore models provides new insights into molecular properties and features that are determinants of activity in whole cells. This study provides novel insights into the key 1D molecular descriptors, 2D chemical substructures and 3D pharmacophores which can be used to mine the chemistry space, prioritizing those molecules with a higher probability of activity against Mtb.

Entities:  

Mesh:

Year:  2010        PMID: 20567770     DOI: 10.1039/b917766c

Source DB:  PubMed          Journal:  Mol Biosyst        ISSN: 1742-2051


  43 in total

1.  Thermodynamic Proxies to Compensate for Biases in Drug Discovery Methods.

Authors:  Sean Ekins; Nadia K Litterman; Christopher A Lipinski; Barry A Bunin
Journal:  Pharm Res       Date:  2015-08-27       Impact factor: 4.200

2.  Computational models for neglected diseases: gaps and opportunities.

Authors:  Elizabeth L Ponder; Joel S Freundlich; Malabika Sarker; Sean Ekins
Journal:  Pharm Res       Date:  2013-08-30       Impact factor: 4.200

3.  Finding promiscuous old drugs for new uses.

Authors:  Sean Ekins; Antony J Williams
Journal:  Pharm Res       Date:  2011-05-24       Impact factor: 4.200

4.  Combining cheminformatics methods and pathway analysis to identify molecules with whole-cell activity against Mycobacterium tuberculosis.

Authors:  Malabika Sarker; Carolyn Talcott; Peter Madrid; Sidharth Chopra; Barry A Bunin; Gyanu Lamichhane; Joel S Freundlich; Sean Ekins
Journal:  Pharm Res       Date:  2012-04-04       Impact factor: 4.200

5.  Bayesian models for screening and TB Mobile for target inference with Mycobacterium tuberculosis.

Authors:  Sean Ekins; Allen C Casey; David Roberts; Tanya Parish; Barry A Bunin
Journal:  Tuberculosis (Edinb)       Date:  2013-12-19       Impact factor: 3.131

Review 6.  Molecule Property Analyses of Active Compounds for Mycobacterium tuberculosis.

Authors:  Vadim Makarov; Elena Salina; Robert C Reynolds; Phyo Phyo Kyaw Zin; Sean Ekins
Journal:  J Med Chem       Date:  2020-04-20       Impact factor: 7.446

Review 7.  Computational databases, pathway and cheminformatics tools for tuberculosis drug discovery.

Authors:  Sean Ekins; Joel S Freundlich; Inhee Choi; Malabika Sarker; Carolyn Talcott
Journal:  Trends Microbiol       Date:  2010-12-02       Impact factor: 17.079

8.  Bayesian models leveraging bioactivity and cytotoxicity information for drug discovery.

Authors:  Sean Ekins; Robert C Reynolds; Hiyun Kim; Mi-Sun Koo; Marilyn Ekonomidis; Meliza Talaue; Steve D Paget; Lisa K Woolhiser; Anne J Lenaerts; Barry A Bunin; Nancy Connell; Joel S Freundlich
Journal:  Chem Biol       Date:  2013-03-21

9.  Essential metabolites of Mycobacterium tuberculosis and their mimics.

Authors:  Gyanu Lamichhane; Joel S Freundlich; Sean Ekins; Niluka Wickramaratne; Scott T Nolan; William R Bishai
Journal:  mBio       Date:  2011-02-01       Impact factor: 7.867

10.  Are bigger data sets better for machine learning? Fusing single-point and dual-event dose response data for Mycobacterium tuberculosis.

Authors:  Sean Ekins; Joel S Freundlich; Robert C Reynolds
Journal:  J Chem Inf Model       Date:  2014-07-17       Impact factor: 4.956

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.